Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. A standard phase I design was used in this study, in which consecutive ...
PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular ...
Madison-based Schering-Plough yesterday agreed to develop and market British Biotechs cancer drug marimastat, in an alliance worth up to $60 million or more depending on potential sales.
(MENAFN- GlobeNewsWire - Nasdaq) Agreement Advances Mission to Address Critical Snakebite Treatment Gap Through the Development of Novel Oral Therapies CORTE MADERA, Calif., Feb. 24, 2026 (GLOBE ...
INVESTORS bought into British Biotech after the pharmaceuticals group revived hopes that its ill-fated cancer drug Marimastat could still have a future - just two months after writing it off. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results